Orencia (abatacept)

P=N/A, N=5000, Recruiting, Duke University | Trial primary completion date: Sep 2026 --> Mar 2027

P1, N=20, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

Agreed positions included caution with JAK inhibitors (JAKi) in older patients and in those with CV/VTE risk; preference for IL-6 receptor inhibitors or JAKi for monotherapy or prominent systemic inflammation; in RA-ILD, use a b/tsDMARD with a non-TNFi mechanism; rituximab as first choice in rheumatoid vasculitis; abatacept in infection-prone patients; discouraging JAKi in prior malignancy; and TNFi as acceptable during pregnancy. Two statements did not reach consensus: preferential use of non-TNFi in obesity and heightened caution with tofacitinib in osteoporosis or fracture risk. This Delphi-validated, profile-based framework provides a practical tool to support evidence-informed clinical decision-making.

P2, N=30, Active, not recruiting, Emory University | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027

P3, N=400, Recruiting, Duke University | Not yet recruiting --> Recruiting

P2, N=160, Recruiting, Boston Children's Hospital | Active, not recruiting --> Recruiting

P2/3, N=45, Not yet recruiting, Duke Clinical Research Institute

P=N/A, N=72, Recruiting, Hospital for Special Surgery, New York | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=20, Not yet recruiting, National Cancer Institute (NCI)

P2, N=27, Active, not recruiting, NYU Langone Health | Trial completion date: Aug 2026 --> Jan 2027 | Trial primary completion date: Aug 2025 --> Jan 2027

P2/3, N=64, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology

We aimed to analyse incident malignancies under treatment with JAKi, tumour necrosis factor inhibitors (TNFi), abatacept (ABA), rituximab (RTX), interleukin 6 inhibitors (IL6i) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs - bionaive) in patients with rheumatoid arthritis (RA) observed in daily rheumatological care. IR of malignancies in selected patients receiving JAKi in a real-world setting was numerically higher than the IR reported for tofacitinib in the Oral Surveillance study. However, we found no statistical evidence of an increased risk of malignancies with JAKi compared to TNFi, although patients on JAKi were older and had longer disease duration and more previous b/tsDMARDs treatments. Further analyses assessing exposure in terms of treatment duration are needed.